肿瘤细胞治疗研究
英文原题：The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer.
The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer.
本综述简要概述了各种细胞疗法的机制和主要靶点。此外，我们将探讨细胞疗法在治疗胰腺癌背景下的前景展望。
胰腺癌被称为“癌中之王”，是一种主要起源于胰腺导管上皮细胞和腺泡细胞的肿瘤。由于其恶性程度高、起病隐匿、早期诊断困难、进展迅速、生存期短，该肿瘤预后极差。细胞免疫治疗是通过特殊技术在体外培养和扩增免疫效应细胞，使其能够选择性靶向恶性细胞，随后将这些修饰后的细胞回输到患者体内，以清除肿瘤细胞并对癌症提供治疗干预。现状：目前，用于胰腺癌治疗的主要细胞治疗模式包括CAR T细胞治疗、TCR T细胞治疗、NK细胞治疗和CAR NK细胞治疗。
本综述简要概述了各种细胞疗法的机制和主要靶点。此外，我们将探讨细胞疗法在治疗胰腺癌背景下的前景展望。
BACKGROUND: Pancreatic cancer, referred to as the "monarch of malignancies," is a neoplastic growth mostly arising from the epithelial cells of the pancreatic duct and acinar cells. This particular neoplasm has a highly unfavorable prognosis due to its marked malignancy, inconspicuous initial manifestation, challenging early detection, rapid advancement, and limited survival duration. Cellular immunotherapy is the ex vivo culture and expansion of immune effector cells, granting them the capacity to selectively target malignant cells using specialized techniques. Subsequently, these modified cells are reintroduced into the patient's organism with the purpose of eradicating tumor cells and providing therapeutic intervention for cancer. PRESENT SITUATION: Presently, the primary cellular therapeutic modalities employed in the treatment of pancreatic cancer encompass CAR T-cell therapy, TCR T-cell therapy, NK-cell therapy, and CAR NK-cell therapy. AIM OF REVIEW: This review provides a concise overview of the mechanisms and primary targets associated with various cell therapies. Additionally, we will explore the prospective outlook of cell therapy in the context of treating pancreatic cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。
